Travere Therapeutics Director Sells Shares Amid Stock Rally
A director of Travere Therapeutics sold 8,000 shares, reducing his direct holdings by 12.21% to 57,500 shares. The transaction, valued at approximately $329,000, was executed via the exercise and immediate sale of stock options. The sale occurred amid a 168% stock price increase, raising questions about the director's confidence in the company's future performance.
Tickers: $TVTX
Topics: executive transactions SEC filings stock options stock sales